Enteropathy Associated T-cell Lymphoma (EATCL) (DBCOND0040556)

Identifiers

Synonyms

Enteropathy-type Intestinal T-cell Lymphoma / Enteropathy- Type T-cell Lymphoma / Enteropathy Associated T Cell Lymphoma / Enteropathy Associated T-cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Enteropathy-type (intestinal) T-cell lymphoma / Enteropathy-associated T-cell lymphoma (morphologic abnormality) / Enteropathy-associated T-cell lymphoma (disorder) / Intestinal T-cell lymphoma / Intestinal T-cell lymphoma NOS / Intestinal T-cell lymphomas / Intestinal T-cell lymphoma (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02742727	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma	Natural Killer Cell	treatment	1 / 2	unknown_status
NCT00901147	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma	Bortezomib Bortezomib D-mannitol Panobinostat	treatment	2	completed
NCT02533700	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL	No drug interventions	treatment	2	unknown_status
NCT01746992	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma	Cyclophosphamide Doxorubicin Etoposide Ifosfamide Methotrexate Pirarubicin Prednisone Vincristine	treatment	4	unknown_status
NCT02588651	A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)	Brentuximab vedotin	treatment	2	active_not_recruiting
NCT03217643	CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.	Brentuximab vedotin	treatment	2	completed
NCT00697346	Study of MLN8237 in Participants With Advanced Hematological Malignancies	Alisertib	treatment	1	completed
NCT04639843	Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma	Azacitidine Doxorubicin Duvelisib Romidepsin	treatment	1	withdrawn
NCT05377827	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	WU-CART-007	treatment	1	recruiting
NCT04803201	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma	Azacitidine Cyclophosphamide Doxorubicin Duvelisib Etoposide Prednisone Vincristine	treatment	2	recruiting
NCT04480788	CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study	No drug interventions	treatment	1	unknown_status
NCT01787409	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	No drug interventions	treatment	Not Available	recruiting
NCT02652715	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	No drug interventions	basic_science	Not Available	completed
NCT03113500	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	Beta-D-Glucose Brentuximab vedotin Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Prednisone	treatment	2	active_not_recruiting
NCT03049449	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Cyclophosphamide Fludarabine	treatment	1	completed
NCT05978141	A Registry for People With T-cell Lymphoma	No drug interventions	Not Available	Not Available	recruiting
NCT01719835	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study	Cisplatin Cyclophosphamide Doxorubicin Gemcitabine Methylprednisolone Prednisolone Vincristine	treatment	2	unknown_status
NCT05475925	A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas	DR-01	treatment	1 / 2	recruiting